Biogen on Tuesday faced tough questions from Wall Street analysts over the $56,000 annual cost of its newly approved Alzheimer’s drug, Aduhelm.
Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer’s drug
Accelerate growth with 1BusinessWorld's Global Business Profile
Sign up for free or use coupon code 1BW50 for 50% discount on your subscription
Sign up now
The Transformational Potential of Agentic AI: Opportunities, Ambitions, and Risks (1/13/2025) - Artificial intelligence (AI) evolves rapidly, transitioning from a tool for… Read more...
Transforming Data Management for Organizational Success (1/12/2025) - Strategies for Simplifying Processes, Enhancing Security, and Driving Efficiency Across… Read more...
Bridging Education and Innovation: EIT Digital’s Blueprint for Europe’s Tech Future (1/10/2025) - How EIT Digital empowers leaders, scales startups, and drives digital… Read more...
Embracing Transformation: The Strategic Imperative of Generative AI (1/7/2025) - Redefining Business Operations and Workforce Potential in the Era of… Read more...
Empowering Global Progress Through Accessible Data Science (1/7/2025) - Democratizing Data Education and Driving Ethical Innovation for a Better… Read more...
Reinventing Finance with Next-Generation AI (12/28/2024) - Ten Transformative Use Cases Elevate Compliance, Efficiency, and Client Value… Read more...